0.000USD0.000盘前交易 07/24, 09:30 (美东)
关键数据
153.355今开
154.280最高
1.61M成交量
38.53市盈率 TTM
11.33市盈率动
4.180股息TTM
0.58%换手率
153.160昨收
152.135最低
128.24M成交额
25.11市盈率静
1.75市净率
2.73%股息率 TTM
3.13%ROA
187.35052周最高
1.00量比
1.68B净利润
275.54M总股本
3.9693每股收益TTM
0.23Beta
6.67%ROE
127.53652周最低
1.40%振幅
46.58%毛利率
42.14B总市值
2.46回报/风险
1.48%风险率
操作建议
碧迪医疗当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名65/200位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价185.39。中期看,股价处于平稳状态。近一个月,市场表现一般,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
收益预测
Zimmer Biomet Holdings Inc
ZBH
31
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
碧迪医疗简介
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
公司代码BDX
公司碧迪医疗
CEOPolen (Thomas E)
网址https://www.bd.com/
公司股东
常见问题
现在碧迪医疗(BDX)的股票是买入、持有还是卖出?
根据分析师评级,碧迪医疗(BDX)的总体评级为买入,目标价格为185.39。
碧迪医疗(BDX)股票的每股收益(EPS TTM)是多少
碧迪医疗(BDX)股票的每股收益(EPS TTM)是5.83。